{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-003795","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.476386+00:00","generated_at":"2026-06-18T00:46:08.506974+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sana reports Q4 net loss $80.4M; cash $434M; SC291 IND cleared, expects clinical data this year","bullets":["Net loss Q4 2022 $80.4M ($0.42/sh) vs $110.7M ($0.60/sh) in Q4 2021; FY2022 net loss $269.5M ($1.43/sh).","Cash and marketable securities $434.0M at Dec 31, 2022, down from $746.9M; cash runway into 2025.","SC291 (CD19-targeted allogeneic CAR T) IND cleared; initial clinical data expected in 2023.","Plans to move manufacturing to Bothell, WA; expects ~$100M cost savings versus Fremont build-out.","Non-GAAP operating cash burn FY2022 $288.3M vs $209.6M; restructuring costs in Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-003795","json":"https://secwatch.observer/filing/0001564590-23-003795.json","markdown":"https://secwatch.observer/filing/0001564590-23-003795.md","text":"https://secwatch.observer/filing/0001564590-23-003795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000156459023003795/0001564590-23-003795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000156459023003795/sana-8k_20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:46:08.506974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79b8e45c2f742f1d578ff1bf3c61548bd673ddac","claim":"Sana Biotechnology, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On March 16, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770121/000156459023003795/0001564590-23-003795-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}